09/01/2020 |
| Bill was the first patient enrolled in a phase I trial at the National Institutes of Health Clinical Center in Bethesda, Maryland, to treat prostate cancer with a novel combination approach involving two immunotherapies: the vaccine PROSTVAC and the drug nivolumab. |
No hay comentarios:
Publicar un comentario